Reynolds Capital Management decreased its stake in shares of Celgene Co. (NASDAQ:CELG) by 49.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The hedge fund owned 3,700 shares of the biopharmaceutical company’s stock after selling 3,600 shares during the period. Reynolds Capital Management’s holdings in Celgene were worth $443,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. Jennison Associates increased its stake in shares of Celgene by 28.3% in the third quarter. Jennison Associates now owns 12,365,141 shares of the biopharmaceutical company’s stock worth $1,337,537,000 after buying an additional 2,728,714 shares during the last quarter. Birchview Capital increased its stake in shares of Celgene by 8.7% in the third quarter. Birchview Capital now owns 796,351 shares of the biopharmaceutical company’s stock worth $86,141,000 after buying an additional 63,798 shares during the last quarter. Bath Savings Trust Company increased its stake in shares of Celgene by 1.9% in the fourth quarter. Bath Savings Trust Company now owns 80,117 shares of the biopharmaceutical company’s stock worth $9,595,000 after buying an additional 1,481 shares during the last quarter. Eagle Asset Management increased its stake in shares of Celgene by 83.7% in the third quarter. Eagle Asset Management now owns 78,876 shares of the biopharmaceutical company’s stock worth $8,532,000 after buying an additional 35,935 shares during the last quarter. Finally, Gerstein Fisher increased its stake in shares of Celgene by 1.5% in the third quarter. Gerstein Fisher now owns 62,674 shares of the biopharmaceutical company’s stock worth $6,779,000 after buying an additional 941 shares during the last quarter.

Celgene Co. (NASDAQ:CELG) traded up 3.18% on Friday, reaching $108.81. The company had a trading volume of 5,659,867 shares. The firm has a market capitalization of $85.49 billion and a price-to-earnings ratio of 54.62. The stock’s 50-day moving average price is $111.78 and its 200 day moving average price is $118.76. Celgene Co. has a 52-week low of $92.98 and a 52-week high of $140.72.

Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, November 5th. The biopharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.01. During the same period in the previous year, the company posted $0.97 EPS. The company earned $2.33 billion during the quarter, compared to analysts’ expectations of $2.40 billion. Celgene’s quarterly revenue was up 17.8% compared to the same quarter last year. On average, equities analysts anticipate that Celgene Co. will post $4.78 earnings per share for the current fiscal year.

A number of analysts have recently commented on the company. Barclays restated an “equal weight” rating and issued a $130.00 target price on shares of Celgene in a research note on Sunday. Wells Fargo restated an “outperform” rating on shares of Celgene in a research note on Friday. Credit Suisse began coverage on Celgene in a research report on Tuesday, January 19th. They set an “outperform” rating and a $149.00 price target on the stock. William Blair reiterated an “outperform” rating on shares of Celgene in a research report on Thursday, January 14th. Finally, Zacks Investment Research upgraded Celgene from a “hold” rating to a “strong-buy” rating and set a $116.00 price target on the stock in a research report on Thursday, January 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, twenty-three have issued a buy rating and four have assigned a strong buy rating to the company. Celgene currently has a consensus rating of “Buy” and a consensus price target of $149.56.

In related news, Director Michael D. Casey sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 23rd. The stock was sold at an average price of $122.11, for a total value of $2,442,200.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ernest Mario sold 40,000 shares of the company’s stock in a transaction that occurred on Monday, December 28th. The shares were sold at an average price of $119.36, for a total value of $4,774,400.00. Following the completion of the sale, the director now directly owns 82,449 shares in the company, valued at approximately $9,841,112.64. The disclosure for this sale can be found here.

Celgene Corporation (NASDAQ:CELG), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.

12 Month Chart for NASDAQ:CELG

Receive News & Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related companies with MarketBeat.com's FREE daily email newsletter.